Stryker Rallies Amid Continued Recovery from Cyber Disruption and Narrowed 2026 Guidance

Stryker Corporation (NYSE: SYK) stock traded at 272.36 as of September 25, 2026, up 0.9%, reflecting investor confidence in the company’s continued momentum following its second‑quarter results and narrowed full-year guidance.

In the second quarter ended June 30, 2026, Stryker delivered a 9.4% year‑over‑year increase in reported net sales to $6.6 billion, including a 9.0% rise in organic net sales—driven entirely by higher unit volume, according to its SEC Form 10‑Q and earnings release.

Reported earnings per diluted share rose 44.1% year‑over‑year to $3.30, while adjusted EPS increased by 17.9% to $3.69. Adjusted operating margin expanded by 170 basis points to 27.4%, with adjusted gross margin at 66%. These robust margin improvements were supported by operational execution and a net tariff benefit, though management noted ongoing costs related to cybersecurity remediation and supply stabilization in the peripheral vascular segment.

The company also narrowed its full‑year 2026 guidance for organic net sales growth to a range of 8.3%–9.3% and adjusted EPS to $14.95–$15.10, signaling increasing confidence in its recovery trajectory and execution capability.

Operational Recovery and Challenges

Stryker emphasized its improved operational footing since the cyber disruption in early 2026. CEO Kevin Lobo noted that significant progress had been made, with facilities running uninterrupted since April and a robust capital equipment order book guiding forward momentum.

However, the company cautioned that supply disruptions in its peripheral vascular unit have resulted in inventory backorders, affecting growth in that segment and creating lingering headwinds into Q4.

Investor Outlook: Stability Amid Recovery

For investors, the strength in organic sales and margin resurgence is encouraging, particularly as it underscores Stryker’s resilience after the March cyberattack. The narrowed guidance reflects improved visibility into operations and backlog fulfillment.

Yet, peripheral vascular supply challenges remain a notable risk, and uncertainty persists around the pace of full recovery. These factors will be worth monitoring through upcoming earnings and operational updates.

Conclusion

Stryker’s Q2 performance and revised guidance illustrate solid recovery and execution in the face of significant disruption. While operational challenges remain in specific segments, the overall trajectory supports confidence in the company’s ability to deliver on its full‑year targets—and may provide a foundation for sustained long‑term growth.

Note: Stock price (272.36, +0.9%) is as of September 25, 2026 and provided as per verified live data and is separate from company‑reported quarterly results.